MiR-204 suppresses the progression of acute myeloid leukemia through HGF/c-Met pathway

References

• Prada-Arismendy J, Arroyave JC, Rothlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2017;31:63–76.
   PubMed Web of Science ®Google Scholar
• Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 2014;15:e382–e394.
   PubMed Web of Science ®Google Scholar
• Saadatpour A, Guo G, Orkin SH, et al. Characterizing heterogeneity in leukemic cells using single-cell gene expression analysis. Genome Biol. 2014;15:525.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051–1062.
   PubMed Web of Science ®Google Scholar
• Meyers J, Yu Y, Kaye JA, et al. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy. 2013;11:275–286.
   PubMedGoogle Scholar
• Gomwalk NE, Umoh UJ, Gosham LT, et al. Influence of climatic factors on rotavirus infection among children with acute gastroenteritis in Zaria, northern Nigeria. J Trop Pediatr. 1993;39:293–297.
   PubMed Web of Science ®Google Scholar
• Wang X, Chen H, Bai J, et al. MicroRNA: an important regulator in acute myeloid leukemia. Cell Biol Int. 2017;41:936–945.
   PubMed Web of Science ®Google Scholar
• Wallace JA, O’Connell RM. MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts. Blood. 2017;130:1290–1301.
   PubMed Web of Science ®Google Scholar
• Zebisch A, Hatzl S, Pichler M, et al. Therapeutic resistance in acute myeloid leukemia: the role of non-coding RNAs. Int J Mol Sci. 2016;17:2080.
   PubMed Web of Science ®Google Scholar
• Zhang R, Tang P, Wang F, et al. Tumor suppressor miR-139-5p targets Tspan3 and regulates the progression of acute myeloid leukemia through the PI3 K/Akt pathway. J Cell Biochem. 2019;120:4423–4432.
   PubMed Web of Science ®Google Scholar
• Dell’Aversana C, Giorgio C, D’Amato L, et al. MiR-194-5p/BCLAF1 deregulation in AML tumorigenesis. Leukemia. 2017;31:2315–2325.
   PubMed Web of Science ®Google Scholar
• Sadras T, Kok CH, Perugini M, et al. MiR-155 as a potential target of IL-3 signaling in primary AML cells. Leuk Res. 2017;57:57–59.
   PubMed Web of Science ®Google Scholar
• Liu J, Guo B, Chen Z, et al. MiR-125b promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell-intrinsic mechanism. Blood. 2017;129:1491–1502.
   PubMed Web of Science ®Google Scholar
• Wallace JA, Kagele DA, Eiring AM, et al. MiR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. Blood. 2017;129:3074–3086.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang Q, Shi G, et al. MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target. Biomed Pharmacother. 2018;97:1189–1194.
   PubMed Web of Science ®Google Scholar
• Butrym A, Rybka J, Baczynska D, et al. Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients. J Exp Clin Cancer Res. 2015;34:68.
   PubMed Web of Science ®Google Scholar
• Butrym A, Lacina P, Kuliczkowski K, et al. Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia. BMC Cancer. 2018;18:107.
   PubMed Web of Science ®Google Scholar
• Wang Z, Luo H, Fang Z, et al. MiR-204 acts as a potential therapeutic target in acute myeloid leukemia by increasing BIRC6-mediated apoptosis. BMB Rep. 2018;51:444–449.
   PubMed Web of Science ®Google Scholar
• Wang Z, Fang Z, Lu R, et al. MicroRNA-204 potentiates the sensitivity of acute myeloid leukemia cells to arsenic trioxide. Oncol Res. 2019: 1035–1042.
   PubMed Web of Science ®Google Scholar
• Noriega-Guerra H, Freitas VM. Extracellular matrix influencing HGF/c-MET signaling pathway: impact on cancer progression. Int J Mol Sci. 2018;19:3300.
   PubMed Web of Science ®Google Scholar
• Bradley CA, Salto-Tellez M, Laurent-Puig P, et al. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol. 2017;14:562–576.
   PubMed Web of Science ®Google Scholar
• Demkova L, Kucerova L. Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma. Mol Cancer. 2018;17:26.
   PubMed Web of Science ®Google Scholar
• Cao HH, Cheng CY, Su T, et al. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion. Mol Cancer. 2015;14:103.
   PubMed Web of Science ®Google Scholar
• Stabile LP, Rothstein ME, Gubish CT, et al. Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF. J Thorac Oncol. 2014;9:1285–1293.
   PubMed Web of Science ®Google Scholar
• Yap TA, Sandhu SK, Alam SM, et al. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine. Curr Drug Targets. 2011;12:2045–2058.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Estey E, et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 2001;15:1165–1170.
   PubMed Web of Science ®Google Scholar
• Kentsis A, Reed C, Rice KL, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012;18:1118–1122.
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Kim DH, et al. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma. 2005;46:885–891.
   PubMed Web of Science ®Google Scholar
• Liu P, Li J, Lu H, et al. Thalidomide inhibits leukemia cell invasion and migration by upregulation of early growth response gene 1. Leuk Lymphoma. 2009;50:109–113.
   PubMed Web of Science ®Google Scholar
• Venneti S, Thompson CB. Metabolic modulation of epigenetics in gliomas. Brain Pathol. 2013;23:217–221.
   PubMed Web of Science ®Google Scholar
• Merino D, Kelly GL, Lessene G, et al. BH3-Mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell. 2018;34:879–891.
   PubMed Web of Science ®Google Scholar
• Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395–419.
   PubMed Web of Science ®Google Scholar
• Garzon R, Garofalo M, Martelli MP, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A. 2008;105:3945–3950.
   PubMed Web of Science ®Google Scholar
• Edwards DK, Watanabe-Smith K, Rofelty A, et al. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood. 2019;6:588–599.
   Google Scholar
• Kentsis A, Reed C, Rice KL, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012;7:1118–1122.
   Google Scholar
• Kim JG, Sohn SK, Kim DH, et al. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma. 2005;6:885–891.
   Google Scholar
• Guo JR, Li W, Wu Y, et al. Hepatocyte growth factor promotes proliferation, invasion, and metastasis of myeloid leukemia cells through PI3K-AKT and MAPK/ERK signaling pathway. Am J Transl Res. 2016;8:3630–3644.
   PubMed Web of Science ®Google Scholar
• Liu H, Li SR, Si Q. Regulation of miRNAs on c-met protein expression in ovarian cancer and its implication. Eur Rev Med Pharmacol Sci. 2017;21:3353–3359.
   PubMed Web of Science ®Google Scholar
• Fernandes Q. MicroRNA: defining a new niche in leukemia. Blood Rev. 2017;31:129–138.
   PubMed Web of Science ®Google Scholar